ResearchIn-Press PreviewBone biologyTherapeutics
Open Access | 10.1172/jci.insight.95042
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Williams, E.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Bagarova, J. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Kerr, G. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Xia, D. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Place, E. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Dey, D. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Shen, Y. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Bocobo, G.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Mohedas, A. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Huang, X. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Sanderson, P. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by Lee, A. in: JCI | PubMed | Google Scholar
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Zheng, W.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Economides, A.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Smith, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Yu, P.
in:
JCI
|
PubMed
|
Google Scholar
|
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Department of Medicine, Harvard Medical School, Boston, United States of America
3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom
4National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, United States of America
5Skeletal Diseases TFA Group, Regeneron Pharmaceuticals, Inc, Tarrytown, United States of America
Find articles by
Bullock, A.
in:
JCI
|
PubMed
|
Google Scholar
|
Published March 11, 2021 - More info
Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues due to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2/ACVR1. From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor. In enzymatic and cell-based assays, saracatinib preferentially inhibited ALK2 compared with other receptors of the BMP/TGFb signaling pathway, and induced dorsalization in zebrafish embryos consistent with BMP antagonism. We further tested the efficacy of saracatinib using an inducible ACVR1Q207D transgenic mouse line, which provides a model of heterotopic ossification, as well as an inducible ACVR1R206H knock-in, which serves as a genetically and physiologically faithful model of FOP. In both models, saracatinib was well tolerated and potently inhibited the development of heterotopic ossification even when administered transiently following soft tissue injury. Together, these data suggest that saracatinib is an efficacious clinical candidate for repositioning in the treatment of FOP, offering an accelerated path to clinical proof of efficacy studies and potentially significant benefits to individuals with this devastating condition.